Avedro is developing technology for corneal crosslinking. The company’s products are used to treat a number of pathologies as well as to enhance Lasik procedure outcomes. Avedro markets several products in Europe and is in late-stage trials in the US. The company went public in February 2019.

LocationWaltham, MA, USA
CEOReza Zadno